Nicholas A. Saccomano
President and CEO at OnKure Therapeutics Inc.
Sits on 1 board. Last updated September 28, 2026
Time on boards
- Boards served
- 1
- Current seats
- 1
- Board service
- 2 years
- Director since
- 2024
2 years of board service in total across 1 board, counting each seat separately. Longest: OnKure Therapeutics Inc., 2 years.
Chief executive roles
Shareholder support
Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
OnKure Therapeutics Inc. May 27, 202595.2%
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Sep 21, 2026 | OnKure Therapeutics Inc. | Open-market sale | −87 | $2.97 | $258 |
| Jun 22, 2026 | OnKure Therapeutics Inc. | Open-market sale | −86 | $4.40 | $378 |
| Mar 23, 2026 | OnKure Therapeutics Inc. | Open-market sale | −86 | $4.16 | $358 |
| Dec 22, 2025 | OnKure Therapeutics Inc. | Open-market sale | −87 | $2.97 | $258 |
| Sep 22, 2025 | OnKure Therapeutics Inc. | Open-market sale | −88 | $2.62 | $231 |
| Jun 23, 2025 | OnKure Therapeutics Inc. | Open-market sale | −88 | $2.38 | $209 |
| Apr 7, 2025 | OnKure Therapeutics Inc. | Open-market sale | −516 | $2.67 | $1,378 |
| Apr 4, 2025 | OnKure Therapeutics Inc. | Open-market sale | −358 | $3.33 | $1,192 |
| Oct 4, 2024 | OnKure Therapeutics Inc. | Grant or award | +4,556 | — | — |
Questions about Nicholas A. Saccomano
What boards is Nicholas A. Saccomano on?
Nicholas A. Saccomano sits on the board of OnKure Therapeutics Inc.
What company is Nicholas A. Saccomano the CEO of?
Nicholas A. Saccomano has been President and CEO of OnKure Therapeutics Inc. since October 2024.
How long has Nicholas A. Saccomano served on boards?
Our records show at least 2 years of board service across 1 board, the earliest from 2024.
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.